TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03770689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib 50 mg
Description: Participants received peposertib 50 milligram (mg) once daily 5 days per week up to 5.5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib 100 mg
Description: Participants received peposertib 100 mg once daily 5 days per week up to 5.5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib 150 mg
Description: Participants received peposertib 150 mg once daily 5 days per week up to 5.5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib 250 mg
Description: Participants received peposertib 250 mg once daily 5 days per week up to 5.5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants received capecitabine at a dose of 825 milligram per square meter (mg/m\^2) twice daily 5 days per week up to 5.5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants received capecitabine at a dose of 825 milligram per square meter (mg/m\^2) twice daily 5 days per week up to 5.5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants received capecitabine at a dose of 825 milligram per square meter (mg/m\^2) twice daily 5 days per week up to 5.5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants received capecitabine at a dose of 825 milligram per square meter (mg/m\^2) twice daily 5 days per week up to 5.5 weeks.
Study: NCT02266277

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1: E-portal message with IVR call
Description: Active electronic patient portal users will be randomized to receive an e-portal message and IVR calls. Both methods of outreach will provide patients with educational information about influenza vaccination, notify patients of local flu clinic schedules and elicit patient response to vaccination status and barriers.
Study: NCT03770689

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Description: Participants received RT 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Description: Participants received RT 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Description: Participants received RT 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Description: Participants received RT 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks.
Study: NCT02465541

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gentle yoga therapy
Description: Mindfulness in Motion is a mindfulness based intervention that is an 8-10 week program for adults interested in learning a practical strategy for stress reduction, intended to be delivered on the worksite or home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Undergo dietary counseling that will include 10 (20-min) nutritional counseling sessions with a registered dietitian.
Study: NCT02266277

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: E-portal message with no IVR call
Description: Active electronic patient portal users will be randomized to receive only an e-portal message. The e-portal message will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
Study: NCT02465541

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Undergo enhanced usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02266277

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 3: No e-portal message with IVR call
Description: Active electronic patient portal users will be randomized to receive an IVR call. The IVR call will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 5: IVR call
Description: Non electronic patient portal users will be randomized to receive an IVR call with educational information about influenza vaccines, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
Study: NCT03159507

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MAG-EPA
Description: Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8.
Study: NCT03900923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 98% pure CBD
Description: A Bayesian optimal interval (BOIN) design was used, such that participants were assigned to cohorts of size 3 receiving doses of 3, 6, or 9 mg/kg/day, depending on the treatment response of participants in prior cohorts. The BOIN design has ended, and two doses have been tested and eliminated (3 and 6 mg/kg/day). We are now examining 9 mg/kg/day exclusively.
Study: NCT03524287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Assisted No.10 Lymph Node Dissections
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Robotic assisted spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma
Study: NCT00260065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20mg/m\^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.
Study: NCT03564821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Ivosidenib is an inhibitor of the protein IDH1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Ivosidenib is an inhibitor of the protein IDH1
Study: NCT03610503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Participants in this arm will listen to music during the EMG testing
Study: NCT04291794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2mg/kg single bolus
Study: NCT02465541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT00952471

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evidence Based Intervention to order set
Description: The order set was altered to include evidence based care items
Study: NCT02840552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluoromethylcholine (18F-FCH)
Description: FCH PET/CT
Study: NCT02532829

Intervention type: OTHER
Intervention: blood sample analysis
Description: Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.

Intervention type: OTHER
Intervention: blood sample analysis
Description: Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.

Intervention type: OTHER
Intervention: blood sample analysis
Description: Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.
Study: NCT01039610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: 600 mg BID, 14 Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 40 mg single dose
Study: NCT02393976

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IMMUNONUTRITION
Description: IMMUNONUTRITION SUPLEMENTS PERIOPERATIVE
Study: NCT02532829

Intervention type: OTHER
Intervention: blood sample analysis
Description: Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.

Intervention type: OTHER
Intervention: blood sample analysis
Description: Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.

Intervention type: OTHER
Intervention: blood sample analysis
Description: Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.

Intervention type: OTHER
Intervention: blood sample analysis
Description: Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.
Study: NCT02393976

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: STANDART NUTRITION
Description: STANDART NUTRITION PERIOPERATIVE
Study: NCT01475331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
Study: NCT04540757

Intervention type: PROCEDURE
Intervention: Surgery
Description: Participants will be randomised to receive surgery as part of multi-modality treatment
Study: NCT02532829

Intervention type: OTHER
Intervention: blood sample analysis
Description: Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.
Study: NCT02430298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
Study: NCT01402206

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Structured patient-centered follow up of depression
Description: All patients who agree to participate in the study are diagnosed by their GP with a diagnostic assessment instrument called PRIME-MD. Participants in the intervention group visit their GPs at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation. We have chosen to use the MADRS/MADRS-S depression rating scale in this study because it is a easy to use standard instrument especially suitable for measuring change in depressive symptoms.~The control group receives treatment as usual (no intervention).
Study: NCT04540757

Intervention type: PROCEDURE
Intervention: No surgery
Description: Participants will be randomised to receive no surgery as part of multi-modality treatment
Study: NCT04291794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Injection [Diprivan]
Description: Tritiated Target-Controlled Infusion
Study: NCT01404013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICS/LABA
Description: Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast 10mg ,every night, for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICS/LABA and Montelukast
Description: Budesonide 160µg and Formoterol 4.5µg, 1puff, twice a day, for 8 weeks; Montelukast 10mg ,take orally ,every night for 8 weeks
Study: NCT03411109

Intervention type: DRUG
Intervention: Hydromorphone Hydrochloride
Description: All intrathecal injections were performed preoperatively using a 22g or 25 g Whitacre or 24g Sprotte spinal needle. The IA regimen, medication(s) and dose(s), was at the discretion of the attending anesthesiologist, and consisted of one of the following regimens: (1) hydromorphone + local anesthetic (IA-L), or (2) hydromorphone only (IA-O). In patients receiving IA, no other interventional locoregional analgesic techniques (such as rectus sheath blocks or transversus abdominis plane blocks) were utilized.

Intervention type: DRUG
Intervention: Hydromorphone Hydrochloride
Description: All intrathecal injections were performed preoperatively using a 22g or 25 g Whitacre or 24g Sprotte spinal needle. The IA regimen, medication(s) and dose(s), was at the discretion of the attending anesthesiologist, and consisted of one of the following regimens: (1) hydromorphone + local anesthetic (IA-L), or (2) hydromorphone only (IA-O). In patients receiving IA, no other interventional locoregional analgesic techniques (such as rectus sheath blocks or transversus abdominis plane blocks) were utilized.
Study: NCT01731730

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: 3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AYX1 Injection 110 mg
Description: 3mL solution for intrathecal injection with 110 mg of AYX1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AYX1 Injection 330 mg
Description: 3mL solution for intrathecal injection with 330 mg of AYX1
Study: NCT03208920

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pro-Omega
Description: Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each Pro-Omega capsule is 550 mg. Must take 4400 mg/day x 6 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ProOmega Placebo
Description: Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA). Each soybean capsule is 550 mg. Must take 4400 mg/day x 6 months.
Study: NCT02170363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist System (LVAS)
Description: Implantation of left ventricular assist device for hemodynamic support
Study: NCT01394614

Intervention type: BIOLOGICAL
Intervention: A/H1N1 vaccine
Description: Verify if exposure to Arepanrix vaccine increase risk of developing narcolepsy in 16 weeks post-vaccination.
Study: NCT03987932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEAT!2
Description: Participants randomized to NEAT!2 will have their NEAT!2 app turned on after randomization. When 30 minutes of continuous non-movement or sedentary time is detected, the NEAT!2 app will provide a vibration or audio notification as well as display a reminder on the phone's lock/home screen. Participants will be asked to use the app for the 3 months of the intervention. Participants will be given an initial goal to reduce total sedentary time by 30 minutes/day, ultimately progressing to a 90 minute/day reduction by 3 months. After the 3-month assessment, participants randomized to NEAT!2 will have the option to continue using the app until 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEAT!2+Calls
Description: Participants in this group will have their NEAT!2 app turned on after randomization. In addition, to receiving the identical app and given the same goals as participants randomized to NEAT!2, NEAT!2+Calls participants will receive 10-15 minute bi-weekly coaching calls. After the 3-month assessment, participants will have the option to continue using the app until 6 months. During this time, participants will not receive any coaching calls.
Study: NCT00048932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Double-blind Abatacept
Description: Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Day 1, 15, and 29.
Study: NCT03987932

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed NEAT!2
Description: Participants randomized to Delayed NEAT!2 will not receive any contact or app between baseline and 3 months. However, after completing the 3-month assessment, participants will receive the NEAT!2 application. Participants will then have the option to use the app between 3 and 6 months.
Study: NCT00917072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Didactic
Description: Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
Study: NCT00779233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine tablets 300 mg
Study: NCT00048932

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double-blind Placebo
Description: Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.
Study: NCT00779233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine tablets 300 mg
Study: NCT05830331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERASS Pathway
Description: Enhanced Recovery After Spinal Surgery
Study: NCT00682292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin (ATG)
Description: Thymoglobulin: 1.25 mg/kg per day from day 0 to day 7 post transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclizumab
Description: Daclizumab: 1mg/kg at day 0, 14, 28, 42 and 56 post transplantation
Study: NCT00050440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 1.3 mg/m2 administered intravenously every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose
Study: NCT00684073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: 2 mg buprenorphine and 8 mg buprenorphine tablets at doses from 2 to 16 mg buprenorphine daily for first two days of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: 2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone tablets at doses from 2/0.5 mg buprenorphine/naloxone to 16/4 mg buprenorphine/naloxone daily for last 3 days of study
Study: NCT02217046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: device replacement(pocket capsule removal)
Description: remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
Study: NCT02619461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise at 70%VO2max on a recumbent bicycle for 30 minutes to investigate the effects of exercise at high intensities on appetite and biomarkers of appetite and inflammation.
Study: NCT00490477

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polymyxin -B fiber hemoperfusion system
Description: two hours treatment for two days
Study: NCT00072098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adenovirus vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: interleukin-12 gene
Study: NCT03539900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
Description: NB medication will combine BUPROPION HYDROCHLORIDE (360 mg/day) and NALTREXONE HYDROCHLORIDE (32 mg/day). Taken daily in pill form.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be inactive and taken daily in pill form.
Study: NCT02890940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pet Therapy
Description: Patients will be asked to complete the standardized QLQ-C30/BN20 questionnaires. Following completion of the questionnaires, a trained pet therapy dog will be brought to the patients for approximately 10 minutes. After approximately 10 minutes, the dog will be removed and the patients will be asked to re-complete the standardized QLQ-C30/BN20 questionnaires. Patients will be photographed and videographed during this time.~Finally, patients will be asked to talk about how their perspectives on life have changed with their diagnosis. These responses will be captured for use in the art exhibit created from images collected during the study.
Study: NCT03652090

Intervention type: PROCEDURE
Intervention: cell sampling
Description: nasal brushing to collect cells
Study: NCT00917072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Didactic+Simulation
Description: Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center
Study: NCT00917072

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
Study: NCT03205852

Intervention type: OTHER
Intervention: questionnaire
Description: fulfillment of questionnaire
Study: NCT00904436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipratropium (Atrovent)
Description: Bronchodilator Treatment: Subjects will inhale 1 unit dose vial of aerosolized ipratropium (500 mcg of ipratropium (Atrovent) mixed in 2.5 ml of saline).
Study: NCT00111176

Intervention type: DEVICE
Group type: OTHER
Intervention: Endovascular repair
Description: Endovascular repair.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical
Description: Surgical endovascular repair